

# Humoral Response to the Pfizer BNT162b2 Vaccine in Patients on Hemodialysis

Clinical Journal of the American Society of Nephrology: CJASN  
16, 1037-1042

DOI: [10.2215/cjn.03500321](https://doi.org/10.2215/cjn.03500321)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1756-1757.	0.4	51
5	Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. <i>Journal of Medical Virology</i> , 2021, 93, 5560-5567.	2.5	64
6	Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?. <i>Diagnostics</i> , 2021, 11, 941.	1.3	45
7	Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study. <i>Journal of Nephrology</i> , 2021, 34, 975-983.	0.9	26
10	Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination. <i>Diagnostics</i> , 2021, 11, 832.	1.3	74
11	Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients prospective cohort study. <i>European Journal of Heart Failure</i> , 2021, 23, 1555-1559.	2.9	71
12	Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. <i>Cmaj</i> , 2021, 193, E793-E800.	0.9	40
13	mRNA COVID-19 Vaccine for People with Kidney Failure: Hope but Prudence Warranted. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 996-998.	2.2	4
14	High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1704-1709.	0.4	87
16	Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2147-2152.	3.0	155
17	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021, 6, eabj1031.	5.6	223
18	Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2435-2438.	3.0	91
19	Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1754-1755.	0.4	10
20	Absence of Antibody Responses and Severe COVID-19 in Patients on Hemodialysis Following mRNA Vaccination. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab337.	0.4	1
21	The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 704773.	2.2	54
22	Immediate Impact of Induction Treatment on Postvaccination SARS-CoV-2 Serology in Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, e135-e136.	0.5	3
23	Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely. <i>American Journal of Transplantation</i> , 2021, 21, 2909.	2.6	33
26	Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2153-2158.	3.0	140

#	ARTICLE	IF	CITATIONS
28	COVID-19 vaccination and dialysis patients: why the variable response. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 440-444.	0.2	18
29	Incidence and course of COVID-19 hospitalizations among patients with familial Mediterranean fever. Rheumatology, 2021, 60, S185-S189.	0.9	9
30	Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD20 antibodies. Haematologica, 2022, 107, 715-720.	1.7	51
31	COVID-19 Vaccination Imperatives in People on Maintenance Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1746-1748.	2.2	8
32	Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults. Biomedicines, 2021, 9, 868.	1.4	5
33	Antibody Status, Disease History, and Incidence of SARS-CoV-2 Infection Among Patients on Chronic Dialysis. Journal of the American Society of Nephrology: JASN, 2021, 32, 1880-1886.	3.0	22
34	A French cohort for assessing COVID-19 vaccine responses in specific populations. Nature Medicine, 2021, 27, 1319-1321.	15.2	14
35	Antibody response to mRNA SARS-CoV-2 vaccines in haemodialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 2234-2238.	1.4	17
38	SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?. Nephrology Dialysis Transplantation, 2021, 36, 1950-1954.	0.4	9
39	COVID-19 vaccination in haemodialysis patients: good things come in threes. Nephrology Dialysis Transplantation, 2021, 36, 1947-1949.	0.4	19
40	Spike and neutralizing antibodies response to COVID-19 vaccination in haemodialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 2239-2245.	1.4	12
41	BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clinical Microbiology and Infection, 2021, 27, 1652-1657.	2.8	263
42	After the pandemic: perspectives on the future trajectory of COVID-19. Nature, 2021, 596, 495-504.	18.7	260
43	Safety and Tolerability of the BNT162b2 mRNA COVID-19 Vaccine in Dialyzed Patients. COViNEPH Project. Medicina (Lithuania), 2021, 57, 732.	0.8	23
44	SARS-CoV-2 infection in chronic kidney disease patients vaccinated with Oxford/AstraZeneca COVID-19 vaccine: initial Indian experience. CKJ: Clinical Kidney Journal, 2021, 14, 2263-2265.	1.4	3
46	Kidney implications of SARS-CoV2 infection in children. Pediatric Nephrology, 2021, , 1.	0.9	9
47	Putative Role of Vitamin D for COVID-19 Vaccination. International Journal of Molecular Sciences, 2021, 22, 8988.	1.8	32
48	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines, 2021, 9, 910.	2.1	50

#	ARTICLE	IF	CITATIONS
49	Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 203-209.	3.0	65
50	The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. <i>Journal of Medical Virology</i> , 2022, 94, 173-177.	2.5	33
51	Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine in a Multicenter Cohort of Nursing Home Residents Receiving Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2021, 78, 766-768.	2.1	14
52	Clinical impact, reactogenicity, and immunogenicity after the first CoronaVac dose in dialysis patients: a phase IV prospective study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2612-2615.	1.4	3
53	COVID-19 Vaccines in Patients with Maintenance Hemodialysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 789.	1.1	14
54	Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. <i>EBioMedicine</i> , 2021, 70, 103524.	2.7	53
55	Is Early COVID-19 in Kidney Transplant Recipients Concerning Enough to Halt Transplantation? A Multicenter Comparative Analysis from India. <i>Transplantation Proceedings</i> , 2021, 53, 2468-2475.	0.3	6
56	Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2. <i>Frontiers in Medicine</i> , 2021, 8, 721286.	1.2	11
58	Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2349-2355.	1.4	50
59	Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers. <i>Microorganisms</i> , 2021, 9, 1725.	1.6	48
60	COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. <i>Frontiers in Immunology</i> , 2021, 12, 704110.	2.2	22
61	The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review. <i>Vaccines</i> , 2021, 9, 885.	2.1	57
62	Normalized protein catabolic rate and lymphopenia drive humoral response to the Pfizer BNT162b2 vaccine in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2140-2142.	0.4	0
63	Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2727-2739.	2.6	197
64	Antibody maintenance 3 months after complete messenger RNA COVID-19 vaccination in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2340-2341.	0.4	9
65	Antibody response after first and second-dose of ChAdOx1-nCoV (Covishield™) and BBV-152 (Covaxin™) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. <i>Vaccine</i> , 2021, 39, 6492-6509.	1.7	95
67	Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring. <i>American Journal of Transplantation</i> , 2022, 22, 786-800.	2.6	41
68	Humoral and cellular immune response to severe acute respiratory syndrome coronavirus-2 vaccination in haemodialysis and kidney transplant patients. <i>Nephrology</i> , 2022, 27, 7-24.	0.7	19

#	ARTICLE	IF	CITATIONS
70	Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?. PLoS ONE, 2021, 16, e0257668.	1.1	33
71	Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis. EBioMedicine, 2021, 71, 103567.	2.7	1
72	Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. JAMA Network Open, 2021, 4, e2123622.	2.8	49
73	Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2022, 79, 137-139.	2.1	12
74	Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD. Kidney International Reports, 2021, 6, 2292-2304.	0.4	96
75	SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis. American Journal of Kidney Diseases, 2022, 79, 185-192.e1.	2.1	116
76	Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 3208-3220.	3.0	74
77	Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccine. Clinical Transplantation, 2021, 35, e14478.	0.8	28
78	Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. American Journal of Kidney Diseases, 2021, 78, 571-581.	2.1	100
79	COVID-19 vaccine does not alter panel reactive antibody or flow cytometric cross match in kidney transplant candidates. Transplant Immunology, 2021, 69, 101469.	0.6	5
80	Kidney Transplantation in Times of Covid-19: Decision Analysis in the Canadian Context. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110403.	0.6	3
81	Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose. CKJ: Clinical Kidney Journal, 2022, 15, 226-234.	1.4	30
82	Reduced CoronaVac vaccine antibody response in patients with chronic kidney disease. International Urology and Nephrology, 2021, , 1.	0.6	0
83	Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients. BMC Immunology, 2021, 22, 70.	0.9	15
84	Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks. Vaccines, 2021, 9, 1130.	2.1	36
85	Update on Coronavirus 2019 Vaccine Guidelines for Transplant Recipients. Transplantation Proceedings, 2022, 54, 1399-1404.	0.3	16
87	Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times. PLoS ONE, 2021, 16, e0257646.	1.1	14
88	Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities. Reviews in Medical Virology, 2022, 32, e2309.	3.9	25

#	ARTICLE	IF	CITATIONS
89	Vaccine breakthrough infections in veterans hospitalized with coronavirus infectious disease-2019: A case series. <i>American Journal of Infection Control</i> , 2022, 50, 273-276.	1.1	6
90	Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 375-381.	0.4	14
91	mRNA-Based Vaccine BNT162b2 Might Reduce Severe Acute Respiratory Syndrome Coronavirus 2 B.1.1.7 Variant Transmission in Japanese Population. <i>Cureus</i> , 2021, 13, e19140.	0.2	0
92	Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease. <i>JAMA Network Open</i> , 2021, 4, e2131749.	2.8	56
93	Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5113.	1.0	17
94	Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1868-1878.	0.4	43
95	Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection). <i>Clinics in Laboratory Medicine</i> , 2022, 42, 111-128.	0.7	8
96	Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. <i>Clinical and Experimental Medicine</i> , 2022, 22, 477-485.	1.9	18
97	Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine. <i>Current Medical Science</i> , 2021, 41, 1081-1086.	0.7	11
98	A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. <i>Kidney International</i> , 2022, 101, 390-402.	2.6	72
99	Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions. <i>Frontiers in Immunology</i> , 2021, 12, 779212.	2.2	35
100	Humoral response to BNT162b2 mRNA COVID-19 vaccine in peritoneal and hemodialysis patients: A comparative study. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 790-796.	0.4	9
101	The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. <i>Transplantation</i> , 2022, 106, 821-834.	0.5	127
102	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 163-177.	2.8	120
103	Comparison of long-term antibody response to mRNA SARS-CoV-2 vaccine among peritoneal dialysis and hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 602-604.	0.4	5
104	Similar humoral immune responses in peritoneal dialysis and haemodialysis patients after two doses of the SARS-CoV-2 vaccine BNT162b2. <i>Peritoneal Dialysis International</i> , 2022, 42, 100-101.	1.1	10
105	Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study. <i>European Journal of Cancer</i> , 2021, , .	1.3	1
106	The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination. <i>Vaccines</i> , 2021, 9, 1420.	2.1	8

#	ARTICLE	IF	CITATIONS
107	Long-term trajectories of SARS-CoV-2 neutralizing antibodies and predictive value of first dose vaccination-induced IgG-antibodies in hemodialysis patients. <i>International Urology and Nephrology</i> , 2021, , 1.	0.6	3
108	Short-Term Immunogenicity Profiles and Predictors for Suboptimal Immune Responses in Patients with End-Stage Kidney Disease Immunized with Inactivated SARS-CoV-2 Vaccine. <i>Infectious Diseases and Therapy</i> , 2022, 11, 351-365.	1.8	10
109	Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients â€” the Vienna Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 780594.	2.2	7
110	Determinants of Immune Response to Antiâ€”SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study. <i>Transplantation</i> , 2022, 106, 842-852.	0.5	21
111	Infection control measures to prevent outbreaks of COVID-19 in Quebec hemodialysis units: a cross-sectional survey. <i>CMAJ Open</i> , 2021, 9, E1232-E1241.	1.1	5
112	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. <i>Science Translational Medicine</i> , 2022, 14, eabl8124.	5.8	143
113	Response to and outcomes of the Pfizer <sc>BNT162B2</sc> vaccine in hemodialysis patientsâ€”A prospective observational study. <i>Hemodialysis International</i> , 2022, 26, 216-222.	0.4	6
115	SARS-CoV-2 mRNA Vaccine Immunogenicity in Hemodialysis Patients: Promising Vaccine Protection That May Be Hindered by Fluid Overload. <i>Kidney and Dialysis</i> , 2022, 2, 44-56.	0.5	2
116	Sixâ€”months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist deviceâ€”supported patients. <i>ESC Heart Failure</i> , 2022, , .	1.4	4
117	Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3â€”5â€”months follow-up. <i>Journal of Nephrology</i> , 2022, 35, 153-164.	0.9	14
118	COVIDâ€”19 and chronic kidney disease: an updated overview of reviews. <i>Journal of Nephrology</i> , 2022, 35, 69-85.	0.9	70
119	Investigation of neutralizing antibody titers after mRNA SARSâ€”CoVâ€”2 vaccination in dialysis patients. <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 53-56.	0.2	0
120	Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis. <i>Journal of Nephrology</i> , 2022, 35, 143-151.	0.9	12
121	Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12â€”weeks in South Korea: A prospective longitudinal study. <i>Vaccine</i> , 2022, 40, 437-443.	1.7	5
122	Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1132-1139.	0.4	12
123	Response to Vaccination Against SARS-CoV-2 in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Involvement. <i>Frontiers in Medicine</i> , 2021, 8, 817845.	1.2	7
124	Optimal Timing of COVID-19 Vaccination in the Peri-Transplant Period: A Single Institution Case Series. <i>Transplantation Proceedings</i> , 2022, 54, 1409-1411.	0.3	1
125	Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study. <i>BMC Nephrology</i> , 2022, 23, 55.	0.8	20

#	ARTICLE	IF	CITATIONS
126	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. <i>PLoS ONE</i> , 2022, 17, e0263328.	1.1	21
127	Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1292.	0.8	17
128	Comparison of Covid-19 antibody status after vaccination between residents in long-term geriatric care and residents assisted-living facilities. <i>Infectious Diseases</i> , 2022, 54, 292-296.	1.4	3
130	Secondary Immunodeficiency Related to Kidney Disease (SIDKD)â€™ Definition, Unmet Need, and Mechanisms. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 259-278.	3.0	35
131	æ—°ăžă, 3ăfăfŠă,  ă,ăfăă, 1ăăă-3/4ăJMă,ăæ²»ç,ăfăăăé². <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 129-136.	0.2	1
132	Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2022, 53, 207-214.	1.4	19
133	Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients. <i>Journal of Nephrology</i> , 2022, 35, 1479-1487.	0.9	18
134	COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. <i>Kidney International</i> , 2022, 101, 883-894.	2.6	82
135	The Humoral Immune Response of the ChAdOx1 nCoV-19 Vaccine in Maintenance Dialysis Patients without Prior COVID-19 Infection. <i>Vaccines</i> , 2022, 10, 338.	2.1	5
136	Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizerâ€™BioNTech) in Patients on Hemodialysis. <i>Vaccines</i> , 2022, 10, 327.	2.1	7
137	Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 476.	0.7	2
138	Distinct B and NKT cell responses shape the delayed response to ChAdOx1 nCoV-19 vaccine in end-stage renal disease. <i>Journal of Infection</i> , 2022, 84, e122-e125.	1.7	0
139	Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients. <i>Frontiers in Immunology</i> , 2022, 13, 858399.	2.2	42
141	Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a caseâ€™control observational study. <i>Renal Replacement Therapy</i> , 2022, 8, 8.	0.3	6
143	SARS-CoV-2 mRNA Vaccine-Induced Cellular and Humoral Immunity in Hemodialysis Patients. <i>Biomedicines</i> , 2022, 10, 636.	1.4	6
144	Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients. <i>Frontiers in Medicine</i> , 2022, 9, 781888.	1.2	7
145	Vaccine Effectiveness Against SARS-CoV-2 Infection and Severe Outcomes in the Maintenance Dialysis Population in Ontario, Canada. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 839-849.	3.0	33
146	Humoral response to viral vector COVID-19 vaccine in hemodialysis patients. <i>Kidney Research and Clinical Practice</i> , 2022, , .	0.9	7



#	ARTICLE	IF	CITATIONS
147	Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose. <i>Vaccines</i> , 2022, 10, 433.	2.1	10
148	Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 827859.	1.2	20
149	Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 845882.	2.2	6
150	Protective antibody response to mRNA-1273 and BNT162b2 vaccines in patients on maintenance haemodialysis: a prospective cohort study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1720-1726.	1.4	2
151	COVID-19 Vaccination Response in Kidney Transplant Recipients With and Without Mycophenolate Mofetil: Follow-up of a Randomized Controlled Trial. <i>Kidney International Reports</i> , 2022, 7, 1433-1434.	0.4	9
152	Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT162b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection. <i>Vaccines</i> , 2021, 9, 1508.	2.1	12
153	Antibody maintenance and breakthrough infections 6 months after complete COVID-19 vaccination with the mRNA-1273 and BNT162b2 vaccines in hemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 818-819.	1.4	5
154	Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation. <i>Journal of Clinical Medicine</i> , 2022, 11, 148.	1.0	17
155	Vaccine-induced immune responses against SARS-CoV-2 infections. <i>Exploration of Immunology</i> , 0, , 356-373.	1.7	0
156	Anti-SARS-CoV-2 S-RBD IgG Antibody Responses after COVID-19 mRNA Vaccine in the Chronic Disorder of Consciousness: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5830.	1.0	1
157	Effectiveness of COVID-19 Vaccines in Patients Under Maintenance Hemodialysis. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 5081-5088.	1.2	11
158	Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up. <i>Frontiers in Medicine</i> , 2021, 8, 796676.	1.2	6
159	Immune Responses to SARS-CoV-2 Infection and Vaccination in Dialysis Patients and Kidney Transplant Recipients. <i>Microorganisms</i> , 2022, 10, 4.	1.6	15
160	Predictors of humoral response to SARS-CoV-2 mRNA vaccine BNT162b2 in patients receiving maintenance dialysis. <i>Antimicrobial Stewardship &amp; Healthcare Epidemiology</i> , 2022, 2, .	0.2	2
161	Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 925-932.	0.7	4
162	SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. <i>Journal of Medical Virology</i> , 2022, 94, 3768-3775.	2.5	13
163	Humoral antibody response to the first dose of the ChAdOx1 nCoV-19 vaccine in Asian patients undergoing hemodialysis. <i>Hemodialysis International</i> , 2022, , .	0.4	2
164	Comparison of COVID-19 Inactivated Virus Vaccine Immunogenicity Between Healthy Individuals and Patients on Hemodialysis: A Single-Center Study From Pakistan. <i>Cureus</i> , 2022, 14, e24153.	0.2	2

#	ARTICLE	IF	CITATIONS
165	Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2090.	1.0	6
166	COVID-19 Vaccine Efficacy and Immunogenicity in End-Stage Renal Disease Patients and Kidney Transplant Recipients. <i>Current Transplantation Reports</i> , 2022, 9, 174-184.	0.9	9
167	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
168	Antibody response to double SARS-CoV-2 mRNA vaccination in Japanese kidney transplant recipients. <i>Scientific Reports</i> , 2022, 12, 6850.	1.6	10
169	Anti-SARS-CoV-2S Antibody Levels in Healthcare Workers 10 Months after the Administration of Two BNT162b2 Vaccine Doses in View of Demographic Characteristic and Previous COVID-19 Infection. <i>Vaccines</i> , 2022, 10, 741.	2.1	3
170	Antibody response after two doses of the BNT162b2 vaccine among healthcare workers of a Greek Covid 19 referral hospital: A prospective cohort study. <i>Heliyon</i> , 2022, 8, e09438.	1.4	2
171	Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France. <i>BMC Nephrology</i> , 2022, 23, 189.	0.8	11
172	Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study. <i>Eurosurveillance</i> , 2022, 27, .	3.9	6
174	Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan: A nationwide cohort study. <i>Therapeutic Apheresis and Dialysis</i> , 2023, 27, 19-23.	0.4	12
175	Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1391-1414.	1.8	8
176	Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis. <i>International Journal of Infectious Diseases</i> , 2022, 122, 327-331.	1.5	1
177	Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study. <i>Journal of Medical Virology</i> , 2022, 94, 4719-4726.	2.5	6
178	ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis. <i>Vaccines</i> , 2022, 10, 959.	2.1	3
179	Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review. <i>Vaccines</i> , 2022, 10, 909.	2.1	6
180	SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 988-996.	0.7	6
181	High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium. <i>Viruses</i> , 2022, 14, 1257.	1.5	7
182	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. <i>International Journal of Translational Medicine</i> , 2022, 2, 275-308.	0.1	1
183	Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination. <i>Journal of Inflammation Research</i> , 0, Volume 15, 3467-3475.	1.6	2

#	ARTICLE	IF	CITATIONS
184	Safety and efficacy of coronavirus diseaseâ€”19 vaccines in chronic kidney disease patients under maintenance hemodialysis: A systematic review. <i>Health Science Reports</i> , 2022, 5, .	0.6	8
185	è...1è†œé€æžã•æ—°ãžã,3ãfãfŠã, ã,ãf«ã,1æ,,ÿæÿ“ç—‡. <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 371-377.	0.2	0
186	BNT162b2 vaccine effectiveness in chronic kidney disease patientsâ€”an observational study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1838-1846.	1.4	2
187	Optimized infection control practices augment the robust protective effect of vaccination for ESRD patients during a hemodialysis facility SARS-CoV-2 outbreak. <i>American Journal of Infection Control</i> , 2022, 50, 1118-1124.	1.1	4
188	Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	6
189	Durability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates: 18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial. <i>Vaccines</i> , 2022, 10, 1091.	2.1	1
190	SARS-CoV-2 Infection during the Omicron Surge among Patients Receiving Dialysis: The Role of Circulating Receptor-Binding Domain Antibodies and Vaccine Doses. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1832-1839.	3.0	13
191	Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 4984.	1.0	6
192	Impact of variant of concern and vaccination status on <sc>COVID</sc>â€”19 infection virological dynamics in end stage kidney disease patients receiving haemodialysis. <i>Nephrology</i> , 2022, 27, 804-809.	0.7	1
193	Vaccination against SARS-CoV-2 in Haemodialysis Patients: Spikeâ€™s Ab Response and the Influence of BMI and Age. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10091.	1.2	2
194	Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis. <i>Renal Replacement Therapy</i> , 2022, 8, .	0.3	7
195	COVID-19 and Renal Failure â€” Adding Insult to Injury? Israelâ€™s Experience Based on Nationwide Retrospective Cohort Study. <i>Journal of General Internal Medicine</i> , 2022, 37, 3128-3133.	1.3	1
196	Efficacy and Safety of COVID-19 Vaccine in Patients on Renal Replacement Therapy. <i>Vaccines</i> , 2022, 10, 1395.	2.1	6
197	Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant. <i>Vaccine</i> , 2022, 40, 6499-6511.	1.7	11
198	The Waxing, Waning, and Predictors of Humoral Responses to Vector-Based SARS-CoV-2 Vaccine in Hemodialysis Patients. <i>Vaccines</i> , 2022, 10, 1537.	2.1	3
199	Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination. <i>IScience</i> , 2022, 25, 105209.	1.9	2
200	Improved Immune Response to the Third COVID-19 mRNA Vaccine Dose in Hemodialysis Patients. <i>Kidney International Reports</i> , 2022, 7, 2718-2721.	0.4	9
201	Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis. <i>PLoS ONE</i> , 2022, 17, e0273676.	1.1	5

#	ARTICLE	IF	CITATIONS
202	Immunogenicity and safety of SARS-CoV-2 vaccine in hemodialysis patients: A systematic review and meta-analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	9
203	COVID-19 vaccination reduces mortality in patients on maintenance hemodialysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
204	Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort. <i>Vaccines</i> , 2022, 10, 1542.	2.1	9
206	Immunogenicity of COVID-19 mRNA vaccines in hemodialysis patients: Systematic review and meta-analysis. <i>Health Science Reports</i> , 2022, 5, .	0.6	7
207	Decrease in neutralizing antibody titers after SARS-CoV-2 vaccination in hemodialysis patients and the booster effect of a third vaccination. <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 589-593.	0.2	0
208	Humoral Response to Hepatitis B and COVID-19 Vaccine among Maintenance Hemodialysis Patients. <i>Vaccines</i> , 2022, 10, 1670.	2.1	1
209	Effectiveness of COVID-19 vaccines in a large European hemodialysis cohort. , 0, 2, .		1
210	Changes in spike protein antibody titer over 90 days after the second dose of SARS-CoV-2 vaccine in Japanese dialysis patients. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	0
211	Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients. <i>Clinical Immunology Communications</i> , 2023, 3, 1-5.	0.5	1
212	COVID-19 clinical outcomes and risk factors in fully vaccinated hemodialysis patients: A single-center prospective cohort study. <i>Ukrainian Journal of Nephrology and Dialysis</i> , 2022, , 43-50.	0.0	0
213	The role of Israeli researchers in the scientific literature regarding COVID-19 vaccines. <i>Israel Journal of Health Policy Research</i> , 2022, 11, .	1.4	2
214	SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis. <i>American Journal of Kidney Diseases</i> , 2023, 81, 406-415.	2.1	11
215	Clinical characteristics and severity of beta and delta variants of SARS-CoV-2 and the effect of vaccine on delta variants. <i>Heliyon</i> , 2022, 8, e12594.	1.4	1
216	Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations. <i>Vaccine: X</i> , 2022, 12, 100246.	0.9	3
217	Assessment of Antibody-Titer Changes after Second and Third Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccination in Japanese Post-Kidney-Transplant Patients. <i>Vaccines</i> , 2023, 11, 134.	2.1	1
218	Waning Humoral Response 6 Month after Double Vaccination with the mRNA-BNT162b2 Vaccine in Hemodialysis Patients. <i>Acta Medica Lituanica</i> , 2023, 30, 3.	0.2	0
220	Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine. <i>Inflammation Research</i> , 2023, 72, 989-1000.	1.6	3
221	Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study. <i>Clinical and Experimental Nephrology</i> , 0, , .	0.7	0

#	ARTICLE	IF	CITATIONS
222	A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ TĀcell profile. <i>Cell Reports Medicine</i> , 2023, 4, 100955.	3.3	1
223	Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines. <i>Life</i> , 2023, 13, 474.	1.1	1
224	Outcomes of vaccinations against respiratory diseases in patients with end-stage renal disease undergoing hemodialysis: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2023, 18, e0281160.	1.1	5
225	Efficacy of vaccination against the SARS-CoV-2 virus in patients with chronic kidney disease on hemodialysis. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	3
226	Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients. <i>Clinical and Experimental Nephrology</i> , 2023, 27, 445-453.	0.7	3
227	Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients. <i>Renal Replacement Therapy</i> , 2023, 9, .	0.3	1
228	Crosstalk between COVID-19 Infection and Kidney Diseases: A Review on the Metabolomic Approaches. <i>Vaccines</i> , 2023, 11, 489.	2.1	3
229	Humeral and cellular immune responses to SARS-CoV-2 vaccination in patients on peritoneal dialysis. <i>Journal of the Formosan Medical Association</i> , 2023, , .	0.8	0
230	T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis. <i>Vaccines</i> , 2023, 11, 653.	2.1	5
231	Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVacĀ and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study. <i>Vaccines</i> , 2023, 11, 715.	2.1	1
232	Humoral Response in Hemodialysis Patients Post-SARS-CoV-2 mRNA Vaccination: A Systematic Review of Literature. <i>Vaccines</i> , 2023, 11, 724.	2.1	16
233	Questionnaire Survey on Vaccination Status and Reasons for Non-immunization with the Novel Coronavirus Vaccine among Dialysis Facility Workers in Okinawa Prefecture. <i>Nihon Toseki Igakkai Zasshi</i> , 2023, 56, 101-107.	0.2	1
234	Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis. <i>Clinical and Experimental Nephrology</i> , 2023, 27, 639-647.	0.7	3
235	Effects of SARS-CoV-2 vaccination on the severity of COVID-19 infection in patients on chronic dialysis. <i>Journal of Nephrology</i> , 0, , .	0.9	1
236	Dialysis modality, humoral response to vaccine, and SARSĀCoVĀ2 infection risk: Comparative prospective evaluation. <i>Seminars in Dialysis</i> , 2023, 36, 382-389.	0.7	1
237	Effect of Lymphocyte Phenotypic Alterations on the Humoral Response to Vaccination Against SARS-COV-2 in Dialysis Patients. <i>Annals of Laboratory Medicine</i> , 2023, 43, 451-460.	1.2	5
238	What has vaccination against COVID-19 in CKD patients taught us?. <i>Journal of Nephrology</i> , 2023, 36, 1257-1266.	0.9	1
258	Comparative Analysis of IgG Antibody Titers Induced by Three Different SARS-COV-2 Vaccines in Healthy Adults of Pakistan. <i>Current Microbiology</i> , 2023, 80, .	1.0	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------